27271087|t|Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6- week, placebo-controlled study
27271087|a|Asenapine is a second generation anti-psychotic approved in the USA in 2009 for the treatment of schizophrenia, but its efficacy has not been proven in Asian patients. The objectives of this study are to evaluate the efficacy and tolerability of asenapine in Asian patients experiencing an acute exacerbation of schizophrenia. In this prospective, double-blind study, patients in Japan, Korea, and Taiwan were randomized (1:1:1) to asenapine 5 mg twice daily (bid), 10 mg bid or placebo for 6 weeks after a 3- to 7- day washout / screening period. The primary endpoint was the mean change in the positive and negative syndrome scale (PANSS) total score from baseline to day 42/ treatment end. Of the 532 participants randomized, 530 received treatment. The primary endpoint was significantly greater with asenapine 5 and 10 mg bid than with placebo (-12.24 and -14.17 vs. -0.95; p < 0.0001). The results of secondary endpoints including PANSS negative subscale scores and PANSS responders at the end of treatment supported the results of the primary endpoint. There were no significant differences in the incidence of treatment -emergent adverse events reported with asenapine 5 and 10 mg bid and placebo (84.6, 80.7, and 81.6 %). There was a mean (± standard deviation) change in weight of -1.76 ± 2.45 kg for placebo, +0.42 ± 2.65 kg for asenapine 5 mg bid, and +0.81 ± 2.89 kg for asenapine 10 mg bid group. Asenapine was effective and generally well tolerated when used for the treatment of acute exacerbations of schizophrenia in Asian patients.
27271087	0	8	Efficacy	T080	C1280519
27271087	13	19	safety	T080	C0678800
27271087	23	32	asenapine	T109,T121	C2000088
27271087	36	41	Asian	T098	C0078988
27271087	42	50	patients	T101	C0030705
27271087	59	77	acute exacerbation	T033	C0743630
27271087	81	94	schizophrenia	T048	C0036341
27271087	98	109	multicentre	T062	C0206012
27271087	111	121	randomized	T062,T170	C0206034
27271087	123	135	double-blind	T062	C0013072
27271087	140	144	week	T079	C0439230
27271087	146	170	placebo-controlled study	T062,T170	C0599724
27271087	171	180	Asenapine	T109,T121	C2000088
27271087	204	218	anti-psychotic	T121	C0040615
27271087	235	238	USA	T083	C0041703
27271087	255	264	treatment	T061	C0087111
27271087	268	281	schizophrenia	T048	C0036341
27271087	291	299	efficacy	T080	C1280519
27271087	323	328	Asian	T098	C0078988
27271087	329	337	patients	T101	C0030705
27271087	343	353	objectives	T170	C0018017
27271087	362	367	study	T062	C2603343
27271087	388	396	efficacy	T080	C1280519
27271087	401	413	tolerability	T080	C1704410
27271087	417	426	asenapine	T109,T121	C2000088
27271087	430	435	Asian	T098	C0078988
27271087	436	444	patients	T101	C0030705
27271087	461	479	acute exacerbation	T033	C0743630
27271087	483	496	schizophrenia	T048	C0036341
27271087	519	537	double-blind study	T062	C0013072
27271087	539	547	patients	T101	C0030705
27271087	551	556	Japan	T083	C0022341
27271087	558	563	Korea	T083	C0022771
27271087	569	575	Taiwan	T083	C0039260
27271087	581	591	randomized	T062	C0034656
27271087	603	612	asenapine	T109,T121	C2000088
27271087	618	629	twice daily	T079	C0585361
27271087	631	634	bid	T079	C0585361
27271087	643	646	bid	T079	C0585361
27271087	650	657	placebo	T062	C1706408
27271087	664	669	weeks	T079	C0439230
27271087	687	690	day	T079	C0439228
27271087	691	698	washout	T079	C1710661
27271087	701	717	screening period	T079	C1948053
27271087	723	739	primary endpoint	T130	C2986535
27271087	767	803	positive and negative syndrome scale	T170	C0451383
27271087	805	810	PANSS	T170	C0451383
27271087	818	823	score	T081	C0449820
27271087	829	837	baseline	T081	C1442488
27271087	841	844	day	T079	C0439228
27271087	849	858	treatment	T061	C0087111
27271087	875	887	participants	T098	C0679646
27271087	888	898	randomized	T062	C0034656
27271087	913	922	treatment	T061	C0087111
27271087	928	944	primary endpoint	T130	C2986535
27271087	976	985	asenapine	T109,T121	C2000088
27271087	998	1001	bid	T079	C0585361
27271087	1012	1019	placebo	T062	C1706408
27271087	1067	1074	results	T169	C1274040
27271087	1078	1097	secondary endpoints	T080	C2349179
27271087	1108	1113	PANSS	T170	C0451383
27271087	1114	1138	negative subscale scores	T081	C0449820
27271087	1143	1148	PANSS	T170	C0451383
27271087	1174	1183	treatment	T061	C0087111
27271087	1198	1205	results	T169	C1274040
27271087	1213	1229	primary endpoint	T130	C2986535
27271087	1276	1285	incidence	T081	C0021149
27271087	1289	1298	treatment	T061	C0087111
27271087	1289	1308	treatment -emergent	T078	C0750573
27271087	1309	1323	adverse events	T046	C0877248
27271087	1338	1347	asenapine	T109,T121	C2000088
27271087	1360	1363	bid	T079	C0585361
27271087	1368	1375	placebo	T062	C1706408
27271087	1422	1440	standard deviation	T081	C0871420
27271087	1482	1489	placebo	T062	C1706408
27271087	1511	1520	asenapine	T109,T121	C2000088
27271087	1526	1529	bid	T079	C0585361
27271087	1555	1564	asenapine	T109,T121	C2000088
27271087	1571	1574	bid	T079	C0585361
27271087	1582	1591	Asenapine	T109,T121	C2000088
27271087	1596	1605	effective	T080	C1704419
27271087	1625	1634	tolerated	T080	C1704410
27271087	1653	1662	treatment	T061	C0087111
27271087	1666	1685	acute exacerbations	T033	C0743630
27271087	1689	1702	schizophrenia	T048	C0036341
27271087	1706	1711	Asian	T098	C0078988
27271087	1712	1720	patients	T101	C0030705